Drug Trial Radar · NCT03281369
A Study of Multiple Immunotherapy-Based Treatment Combinations in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Cancer (G/GEJ) or Esophageal Cancer (Morpheus-Gastric and Esophageal Cancer)
Last checked: Nov 19, 2026Latest source record: Aug 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
219
Actual
Start
Oct 13, 2017
Primary completion
Oct 9, 2025
Study completion Oct 9, 2025
Sponsor
- Lead sponsor
- Hoffmann-La RocheRoche (Genentech) (RHHBY)
- Sponsor type
- Industry
- Collaborators
- Halozyme Therapeutics; BioLineRx, Ltd.
- First posted
- Sep 13, 2017
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A Phase Ib/II, open label, multi-center, randomized study designed to assess the safety, tolerability, pharmacokinetics and preliminary anti-tumor activity of immunotherapy-based treatment combinations in patients with locally advanced unresectable or metastatic G/GEJ cancer (hereafter referred to as gastric cancer) and esophageal cancer. Two cohorts of patients with gastric cancer have been enrolled in parallel in this study: the second-line (2L) Gastric Cancer Cohort consists of patients with gastric cancer who have progressed after receiving a platinum-containing or fluoropyrimide-containing chemotherapy regimen in the first-line setting, and the first-line (1L) Gastric Cancer Cohort consists of patients with gastric cancer who have not received prior chemotherapy in this setting. In each cohort, eligible patients will be assigned to one of several treatment arms. Additionally, a cohort of patients with esophageal cancer who have not received prior systemic treatment for their disease will be enrolled in this study. Eligible patients will be randomized to chemotherapy or the combination of chemotherapy with checkpoint inhibitor immunotherapy.
Conditions
- Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma or Esophageal Carcinoma
Interventions
5-Fluorouracil (5-FU)Drug
5-FU 2400 milligrams per square meter (mg/m\^2) by continuous intravenous (IV) infusion over 46 hours on Days 1 and 2 and Days 15 and 16 of every 28-day cycle.
LeucovorinDrug
Leucovorin: 100 mg/m\^2 IV over 2 hours on Days 1 and 15 of every 28-day cycle.
OxaliplatinDrug
Oxaliplatin: 100 mg/m\^2 administered by IV infusion over 2 hours on Days 1 and 15 of every 28-day cycle.
AtezolizumabDrug
Atezolizumab: 840 mg by IV infusion on Days 1 and 15 of every 28-day cycle.
CobimetinibDrug
Cobimetinib: 60 mg by mouth once a day on Days 1-21 of every 28-day cycle
RamucirumabBiological
Ramucirumab: 8 mg/kg administered by IV infusion over 60 minutes on Days 1 and 15 of every 28-day cycle.
PaclitaxelDrug
Paclitaxel: 80 mg/m\^2 administered by IV infusion on Days 1, 8, and 15 of every 28-day cycle.
PEGylated recombinant human hyaluronidase (PEGPH20)Biological
PEGPH20: 3 micrograms per kilogram (mcg/kg) administered by IV infusion on Days 1, 8, and 15 of every 21-day cycle.
BL-8040Drug
BL-8040: 1.25 mg/kg administered by subcutaneous (SC) injection on Days 1-5 during the 5-day priming period prior to Cycle 1; 1.25 mg/kg administered by SC injection three times a week (Days 1, 3, 5, 8, 10, 12, 15, 17, and 19 of every 21-day cycle).
LinagliptinDrug
Linagliptin: 5 mg orally once a day of every 21-day cycle.
AtezolizumabDrug
Atezolizumab: 1200 mg administered by IV infusion on Day 1 of every 21-day cycle
CobimetinibDrug
Cobimetinib: 40 or 60 mg (depending on the recommended dose determined during the safety run-in phase) by mouth once a day on Days 1-21 of every 28-day cycle.
CisplatinDrug
Cisplatin: 80 mg/m\^2 administered by IV infusion on Day 1 of each 21 day cycle. Treatment will be capped after 6 doses.
TiragolumabDrug
Tiragolumab: 600 mg administered by IV infusion on Day 1 of every 21 day cycle.
5-Fluorouracil (5-FU)Drug
5-FU 800 mg/m\^2 administerd by IV infusion on Days 1-5 of each 21 day cycle.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Stage 1: Percentage of Participants With Objective Response (OR), as Determined by Investigator According to RECIST v1.1Time frame: From randomization up to approximately 84.2 months
Locations
28 sites in 7 countries. Site status is shown where the registry gives one.
Mayo Clinic Cancer Center
Scottsdale, Arizona
Uni of Southern California
Los Angeles, California
UCLA Jonsson Comprehensive Cancer Center
Santa Monica, California
Columbia University Medical Center
New York, New York
Tennessee Oncology - Nashville
Nashville, Tennessee
The University of Texas MD Anderson Cancer Center
Houston, Texas
Blacktown Hospital
Blacktown, New South Wales, Australia
Monash Medical Centre-Moorabbin Campus
Clayton, Victoria, Australia
Peter MacCallum Cancer Centre
Melbourne, Victoria, Australia
Rambam Health Care Campus
Haifa, Israel
Sourasky Medical Centre
Tel Aviv, Israel
Seoul National University Bundang Hospital
Gyeonggi-do, South Korea
Korea University Anam Hospital
Seoul, South Korea
Seoul National University Hospital
Seoul, South Korea
Samsung Medical Center
Seoul, South Korea
Yonsei University College of Medicine (YUCM)-Yonsei Cancer Center
Seoul, South Korea
University of Ulsan College of Medicine - Asan Medical Center (AMC) - Asan Cancer Center (ACC)
Songpa-gu, South Korea
The Catholic University of Korea St. Vincent's Hospital
Suwon, South Korea
Hospital Universitari Vall dHebron
Barcelona, Spain
Universidad de Navarra - Clinica Universitaria de Navarra (CUN)
Pamplona, Navarre, Spain
National Cheng Kung University Hospital
Tainan, Taiwan
National Taiwan University Hospital
Taipei, Taiwan
Taipei Veterans General Hospital
Taipei, Taiwan
Beatson West of Scotland Cancer Centre
Glasgow, United Kingdom
Barts and The London School of Medicine and Dentistry - Barts Cancer Institute (BCI)-CECM
London, United Kingdom
The Royal Marsden
London, United Kingdom
The Christie NHS Foundation Trust
Manchester, United Kingdom
The Royal Marsden NHS Foundation Trust - Royal Marsden Hospital (RMH) - Sutton
Sutton, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.